Compton Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-6,724
| Closed | -$558K | – | 23 |
|
|
2023
Q1 | $558K | Sell |
6,724
-9,393
| -58% | -$778K | 1.2% | 27 |
|
|
2022
Q4 | $1.38M | Sell |
16,117
-3,040
| -16% | -$241K | 1% | 29 |
|
|
2022
Q3 | $1.18M | Sell |
19,157
-1,294
| -6% | -$81.6K | 0.79% | 35 |
|
|
2022
Q2 | $1.26M | Sell |
20,451
-2,131
| -9% | -$132K | 0.7% | 37 |
|
|
2022
Q1 | $1.34M | Hold |
22,582
| – | – | 0.38% | 63 |
|
|
2021
Q4 | $1.64M | Buy |
22,582
+340
| +2% | +$23.4K | 0.43% | 57 |
|
|
2021
Q3 | $1.55M | Sell |
22,242
-6,038
| -21% | -$424K | 0.46% | 56 |
|
|
2021
Q2 | $1.95M | Buy |
28,280
+1,037
| +4% | +$69.2K | 0.57% | 48 |
|
|
2021
Q1 | $1.76M | Sell |
27,243
-150
| -0.5% | -$9.67K | 0.55% | 50 |
|
|
2020
Q4 | $1.6M | Buy |
27,393
+1,225
| +5% | +$73.9K | 0.54% | 48 |
|
|
2020
Q3 | $1.65M | Sell |
26,168
-1,155
| -4% | -$80.1K | 0.64% | 44 |
|
|
2020
Q2 | $2.1M | Sell |
27,323
-25,660
| -48% | -$1.97M | 0.88% | 38 |
|
|
2020
Q1 | $3.96M | Sell |
52,983
-1,575
| -3% | -$109K | 1.95% | 11 |
|
|
2019
Q4 | $3.54M | Sell |
54,558
-2,395
| -4% | -$156K | 1.37% | 20 |
|
|
2019
Q3 | $3.61M | Hold |
56,953
| – | – | 1.52% | 18 |
|
|
2019
Q2 | $3.85M | Buy |
56,953
+50
| +0.1% | +$3.29K | 1.63% | 14 |
|
|
2019
Q1 | $3.7M | Hold |
56,903
| – | – | 1.61% | 15 |
|
|
2018
Q4 | $3.56M | Sell |
56,903
-1,490
| -3% | -$104K | 1.7% | 14 |
|
|
2018
Q3 | $4.51M | Sell |
58,393
-1,290
| -2% | -$97.4K | 1.78% | 10 |
|
|
2018
Q2 | $4.23M | Sell |
59,683
-547
| -0.9% | -$38.6K | 1.79% | 9 |
|
|
2018
Q1 | $4.54M | Sell |
60,230
-710
| -1% | -$56.4K | 1.93% | 9 |
|
|
2017
Q4 | $4.37M | Sell |
60,940
-1,420
| -2% | -$108K | 1.86% | 8 |
|
|
2017
Q3 | $5.05M | Sell |
62,360
-3,735
| -6% | -$286K | 2.27% | 6 |
|
|
2017
Q2 | $4.68M | Buy |
66,095
+796
| +1% | +$53K | 2.13% | 9 |
|
|
2017
Q1 | $4.43M | Sell |
65,299
-91
| -0.1% | -$6.4K | 2.18% | 8 |
|
|
2016
Q4 | $4.68M | Sell |
65,390
-66,960
| -51% | -$4.98M | 2.45% | 7 |
|
|
2016
Q3 | $10.8M | Buy |
132,350
+66,140
| +100% | +$5.37M | 2.98% | 6 |
|
|
2016
Q2 | $5.52M | Sell |
66,210
-755
| -1% | -$67K | 3.09% | 5 |
|
|
2016
Q1 | $6.15M | Buy |
66,965
+570
| +0.9% | +$51.4K | 3.46% | 3 |
|
|
2015
Q4 | $6.72M | Sell |
66,395
-1,010
| -1% | -$105K | 3.8% | 2 |
|
|
2015
Q3 | $6.62M | Sell |
67,405
-2,380
| -3% | -$264K | 2.38% | 2 |
|
|
2015
Q2 | $8.17M | Sell |
69,785
-300
| -0.4% | -$32.8K | 4.49% | 2 |
|
|
2015
Q1 | $5.88M | Sell |
70,085
-650
| -0.9% | -$66K | 3.27% | 4 |
|
|
2014
Q4 | $6.67M | Sell |
70,735
-2,365
| -3% | -$245K | 3.63% | 3 |
|
|
2014
Q3 | $7.78M | Sell |
73,100
-4,420
| -6% | -$433K | 4.24% | 3 |
|
|
2014
Q2 | $6.43M | Buy |
77,520
+280
| +0.4% | +$21.8K | 3.47% | 3 |
|
|
2014
Q1 | $5.47M | Sell |
77,240
-500
| -0.6% | -$39.2K | 3.16% | 5 |
|
|
2013
Q4 | $5.84M | Hold |
77,740
| – | – | 3.33% | 4 |
|
|
2013
Q3 | $4.89M | Buy |
77,740
+300
| +0.4% | +$17.9K | 2.98% | 7 |
|
|
2013
Q2 | $3.97M | Buy |
+77,440
| New | +$4.04M | 2.45% | 8 |
|
Other funds holding GILD
Compton Capital Management's GILD Position: Q2 2023 in Review
Compton Capital Management sold out of Gilead Sciences (GILD) in Q2 2023, closing a stake of 6,724 shares — an estimated $558K sold.
Compton Capital Management first reported a position in GILD in Q2 2013 and held it in 40 quarters. The position peaked at $10.8M in Q3 2016. 1,701 funds tracked by Wall St. Rank hold GILD as of Q2 2023.
- Compton Capital Management reported no remaining Gilead Sciences position as of Q2 2023 after selling out during the quarter.
- Compton Capital Management sold 6,724 Gilead Sciences shares in Q2 2023, an estimated $558K.
- Compton Capital Management first reported a position in Gilead Sciences in Q2 2013 and held it in 40 quarters.
- Compton Capital Management's Gilead Sciences position peaked at $10.8M in Q3 2016.
- 1,701 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2023.
Based on Compton Capital Management's 13F filing for Q2 2023, filed 9 Aug 2023.